Avalyn Pharma Inc. Common Stock AVLN

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

• GlobeNewswire Inc. 24 ago

  Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026

  Avalyn Pharma announced two poster presentations at the European Respiratory Society International Congress 2026 in Barcelona. The presentations will cover patient perspectives on IPF clinical trial participation and in silico modeling of AP01, the company's nebulized pirfenidone formulation. Avalyn has completed enrollment of its Phase 2b MIST trial with 398 patients, with topline data expected in the second half of 2027.

  

• GlobeNewswire Inc. 17 jun

  Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis

  Avalyn Pharma announced completion of target enrollment of 375 patients in the Phase 2b MIST clinical trial of AP01 (inhaled pirfenidone) for progressive pulmonary fibrosis. The global, randomized, double-blinded, placebo-controlled trial is evaluating two doses of AP01 against placebo, with primary endpoint measuring change in lung function at 52 weeks. Topline data is expected in the second half of 2027.